JP6889771B2 - ドライアイ症候群を治療する方法 - Google Patents

ドライアイ症候群を治療する方法 Download PDF

Info

Publication number
JP6889771B2
JP6889771B2 JP2019503485A JP2019503485A JP6889771B2 JP 6889771 B2 JP6889771 B2 JP 6889771B2 JP 2019503485 A JP2019503485 A JP 2019503485A JP 2019503485 A JP2019503485 A JP 2019503485A JP 6889771 B2 JP6889771 B2 JP 6889771B2
Authority
JP
Japan
Prior art keywords
eye
subject
tear film
pharmaceutical composition
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019503485A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019525923A5 (enExample
JP2019525923A (ja
Inventor
ウォンスク ヤン
ウォンスク ヤン
シンウク カン
シンウク カン
キョンスン キム
キョンスン キム
Original Assignee
リジェンツリー リミテッド ライアビリティ カンパニー
リジェンツリー リミテッド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リジェンツリー リミテッド ライアビリティ カンパニー, リジェンツリー リミテッド ライアビリティ カンパニー filed Critical リジェンツリー リミテッド ライアビリティ カンパニー
Publication of JP2019525923A publication Critical patent/JP2019525923A/ja
Publication of JP2019525923A5 publication Critical patent/JP2019525923A5/ja
Application granted granted Critical
Publication of JP6889771B2 publication Critical patent/JP6889771B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2019503485A 2016-07-18 2017-07-17 ドライアイ症候群を治療する方法 Active JP6889771B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662363565P 2016-07-18 2016-07-18
US201662363592P 2016-07-18 2016-07-18
US62/363,592 2016-07-18
US62/363,565 2016-07-18
US201662436727P 2016-12-20 2016-12-20
US62/436,727 2016-12-20
PCT/US2017/042382 WO2018017479A1 (en) 2016-07-18 2017-07-17 Methods of treating dry eye syndrome

Publications (3)

Publication Number Publication Date
JP2019525923A JP2019525923A (ja) 2019-09-12
JP2019525923A5 JP2019525923A5 (enExample) 2019-10-24
JP6889771B2 true JP6889771B2 (ja) 2021-06-18

Family

ID=60992530

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019503485A Active JP6889771B2 (ja) 2016-07-18 2017-07-17 ドライアイ症候群を治療する方法

Country Status (8)

Country Link
US (2) US10960051B2 (enExample)
EP (1) EP3484497A4 (enExample)
JP (1) JP6889771B2 (enExample)
KR (1) KR102488796B1 (enExample)
CN (1) CN109789182A (enExample)
AU (1) AU2017300268B2 (enExample)
CA (1) CA3031069A1 (enExample)
WO (1) WO2018017479A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022102757A (ja) * 2020-12-25 2022-07-07 ライオン株式会社 機械学習実行プログラム、ドライアイ検査プログラム、機械学習実行装置及びドライアイ検査装置
JP7570229B2 (ja) * 2020-12-25 2024-10-21 ライオン株式会社 機械学習実行プログラム、ドライアイ検査プログラム、機械学習実行装置及びドライアイ検査装置
JP7570228B2 (ja) * 2020-12-25 2024-10-21 ライオン株式会社 機械学習実行プログラム、ドライアイ検査プログラム、機械学習実行装置及びドライアイ検査装置

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991012808A1 (en) 1990-02-22 1991-09-05 Macnaught Pty Limited Artificial tears
US20080096817A1 (en) * 1998-07-30 2008-04-24 Regenerx Biopharmaceuticals, Inc. METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN BETA 4 (Tbeta4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES
CN101195025A (zh) * 2001-03-15 2008-06-11 雷金纳克斯生物制药公司 胸腺素β4、类似物、异构体及其它衍生物在制备治疗眼睛和周围组织失调的药物中的应用
CA2458883C (en) * 2001-08-29 2017-11-28 Regenerx Biopharmaceuticals, Inc. Methods of healing or preventing inflammation, damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4, analogues, isoforms and other derivatives
JP2008526986A (ja) * 2005-01-13 2008-07-24 リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド 神経変性疾患、筋変性疾患または神経筋変性疾患による組織の変敗、傷害または損傷の治療方法または予防の方法あるいは前記疾患によって悪影響を受ける組織の修復方法
CN101198344A (zh) * 2005-06-17 2008-06-11 雷金纳克斯生物制药公司 冻干的或可冻干形式的lkktet和/或lkktnt肽组合物
KR20080033939A (ko) * 2005-06-17 2008-04-17 리지너크스 바이오 파마소티컬스, 인코포레이티드 동결 건조된 형태이거나, 또는 동결 건조될 수 있는 형태인엘케이케이티이티 및/또는 엘케이케이티엔티 펩티드조성물들
CN101152568A (zh) * 2006-09-25 2008-04-02 宝勒日 具有促进血管形成、组织再生及伤口愈合作用的多肽组合制剂
CN101743009A (zh) * 2007-07-11 2010-06-16 辉瑞大药厂 治疗干眼病的药物组合物和方法

Also Published As

Publication number Publication date
US10960051B2 (en) 2021-03-30
US20190240294A1 (en) 2019-08-08
CN109789182A (zh) 2019-05-21
AU2017300268A1 (en) 2019-01-31
EP3484497A4 (en) 2020-01-01
JP2019525923A (ja) 2019-09-12
KR102488796B1 (ko) 2023-01-13
AU2017300268B2 (en) 2024-06-13
CA3031069A1 (en) 2018-01-25
KR20190031280A (ko) 2019-03-25
EP3484497A1 (en) 2019-05-22
WO2018017479A1 (en) 2018-01-25
US20210213103A1 (en) 2021-07-15

Similar Documents

Publication Publication Date Title
Arita et al. Comparison of the long-term effects of various topical antiglaucoma medications on meibomian glands
Mastropasqua et al. Conjunctival goblet cells density and preservative‐free tafluprost therapy for glaucoma: an in vivo confocal microscopy and impression cytology study
RU2700927C2 (ru) Офтальмологическая композиция, содержащая циклоспорин и трегалозу
KR20190100283A (ko) 건성 안 질환 치료용 안구 조성물
WO2006064672A1 (ja) 眼疾患治療剤
WO2010027743A1 (en) Pharmaceutical compositions and methods for the treatment of dry eye
Cumurcu et al. Comparison of dose-related ocular side effects during systemic isotretinoin administration
CN105848651A (zh) 干眼症治疗用滴眼剂
US20210213103A1 (en) Methods of treating dry eye syndrome
Cheema et al. Sodium hyaluronate eye drops in the treatment of dry eye disease: an open label, uncontrolled, multi-centre trial
Kanamoto et al. Comparison of the toxicity profile of benzalkonium chloride-preserved tafluprost and SofZia-preserved travoprost applied to the ocular surface
Heitzmann et al. A review of the efficacy, safety and tolerability of Lacrycon® eye drops for the treatment of dry eye syndrome
Easty et al. Comparison of a non-preserved 0.1% T-Gel eye gel (single dose unit) with a preserved 0.1% T-Gel eye gel (multidose) in ocular hypertension and glaucomatous patients
AU2006260184A1 (en) Prophylactic or therapeutic agent for corneal/conjunctival disease
Kumagami et al. Comparison of Corneal Safety and Intraocular Pressure–Lowering Effect of Tafluprost Ophthalmic Solution with Other Prostaglandin Ophthalmic Solutions
JPWO2010107069A1 (ja) アミノ酸含有眼科用組成物
EP3338792B1 (en) Corneal damage prevention/treatment composition comprising thymosin beta 4 and citric acid as active ingredients
Tu et al. Dry eye
CN118510520A (zh) 用于治疗眼部疾病的霉酚酸和/或倍他米松的药物组合物
HK40012612A (en) Methods of treating dry eye syndrome
TW202033213A (zh) 脂聯素擬肽調配物
US20260021159A1 (en) Stable peptide compositions and methods of use thereof for treatment of moderate/severe dry eye-related ocular symptoms
JP2025520875A (ja) 中等度／重度のドライアイ関連眼症状の処置のための安定なペプチド組成物およびその使用方法
Yuksel Evaluation of ocular surface disease associated with glaucoma patients
CN117440821A (zh) 用ngf治疗神经性角膜疼痛

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190816

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190816

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200803

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201109

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210422

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210521

R150 Certificate of patent or registration of utility model

Ref document number: 6889771

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250